Abstract
The relative benefits and risks of nanomedicine have led to global indecisiveness regarding a suitable approach for regulation of this industry, and Australia is no exception. This article proposes a meta-regulation approach for regulating nanomedicine in Australia, demonstrating how this approach enables companies to surpass their compliance requirements and improve stakeholders’ capacity to deal with the inherent uncertainty surrounding the emergent science of nanotechnology.
Get full access to this article
View all access options for this article.